23 February 2011

UCLB’s spin-out company, Spirogen Ltd., announces a research collaboration and licence agreement with Genentech for the discovery and development of antibody drug conjugates.

“We are hopeful that this collaboration with Genentech will allow us to accelerate the development of ADCs based on our potent PBD drugs with one of the leading companies in the ADC field,” said Christopher Martin, CEO of Spirogen.